(EMR) Emerson Electric - Ratings and Ratios
Valves, Instruments, Actuators, Controllers, Tools
EMR EPS (Earnings per Share)
EMR Revenue
Description: EMR Emerson Electric
Emerson Electric Co. (NYSE: EMR) is a diversified technology and software firm headquartered in St. Louis, Missouri, with operations spanning the Americas, Asia, the Middle East, Africa, and Europe.
The business is organized into six segments: Final Control; Measurement & Analytical; Discrete Automation; Safety & Productivity; Control Systems & Software; and Test & Measurement. Across these segments the company supplies a broad portfolio that includes control, isolation, shut-off, pressure-relief, and safety valves, as well as actuators and regulators for process and hybrid industries.
Its instrumentation line measures key physical properties of liquids and gases-pressure, temperature, level, flow, acoustics, corrosion, pH, conductivity, water quality, toxic gases, and flame detection-while its valve and pneumatic offerings cover solenoid and pneumatic valves, position indicators, cylinders, air-preparation equipment, and electric linear-motion solutions.
Emerson also delivers automation hardware such as programmable control systems, electrical distribution gear, and materials-joining technologies, complemented by a professional-tool segment that serves both contractors and homeowners with pipe-working, hydraulic, and electrical tools.
On the software side, the firm provides control-system architectures, safety-instrumented systems, SCADA platforms, digital-twin and asset-performance-management tools, and cybersecurity solutions. Its test-and-measurement business offers software-connected automated systems, while its asset-optimization suite leverages decades of modeling, simulation, and optimization to improve industrial performance.
Key recent metrics: FY 2023 revenue reached $20.5 billion, operating margin held near 14 percent, and free cash flow topped $2.1 billion; the dividend yield is roughly 2.5 percent with a five-year payout growth rate of about 6 percent. The Discrete Automation and Control Systems & Software segments have been the primary drivers of double-digit top-line growth, reflecting robust capital-expenditure cycles in oil-&-gas, chemicals, and the expanding renewable-energy infrastructure.
Sector-level trends that underpin Emerson’s outlook include accelerating industrial automation adoption, heightened focus on energy-transition assets that require advanced process control, and increasing regulatory pressure for safety-instrumented systems-factors that collectively boost demand for Emerson’s integrated hardware-software solutions.
For a deeper dive into Emerson’s valuation metrics and scenario analysis, the ValueRay platform offers a transparent, data-driven view worth checking out.
EMR Stock Overview
Market Cap in USD | 74,881m |
Sub-Industry | Electrical Components & Equipment |
IPO / Inception | 1972-06-01 |
EMR Stock Ratings
Growth Rating | 73.7% |
Fundamental | 68.2% |
Dividend Rating | 52.9% |
Return 12m vs S&P 500 | 4.41% |
Analyst Rating | 4.27 of 5 |
EMR Dividends
Dividend Yield 12m | 1.62% |
Yield on Cost 5y | 3.35% |
Annual Growth 5y | 1.19% |
Payout Consistency | 100.0% |
Payout Ratio | 36.0% |
EMR Growth Ratios
Growth Correlation 3m | -64.4% |
Growth Correlation 12m | 52.5% |
Growth Correlation 5y | 78.9% |
CAGR 5y | 19.66% |
CAGR/Max DD 3y (Calmar Ratio) | 0.66 |
CAGR/Mean DD 3y (Pain Ratio) | 2.66 |
Sharpe Ratio 12m | 0.69 |
Alpha | -1.30 |
Beta | 1.279 |
Volatility | 29.58% |
Current Volume | 2624.3k |
Average Volume 20d | 2634.3k |
Stop Loss | 126.3 (-3%) |
Signal | 0.01 |
Piotroski VR‑10 (Strict, 0-10) 8.0
Net Income (2.65b TTM) > 0 and > 6% of Revenue (6% = 1.07b TTM) |
FCFTA 0.06 (>2.0%) and ΔFCFTA 3.85pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
NWC/Revenue -9.34% (prev 7.24%; Δ -16.58pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
CFO/TA 0.07 (>3.0%) and CFO 3.17b > Net Income 2.65b (YES >=105%, WARN >=100%) |
Net Debt (12.65b) to EBITDA (4.72b) ratio: 2.68 <= 3.0 (WARN <= 3.5) |
Current Ratio 0.85 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
Outstanding Shares last Quarter (564.7m) change vs 12m ago -1.76% (target <= -2.0% for YES) |
Gross Margin 47.38% (prev 44.70%; Δ 2.68pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
Asset Turnover 40.35% (prev 37.21%; Δ 3.14pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
Interest Coverage Ratio 9.21 (EBITDA TTM 4.72b / Interest Expense TTM 343.0m) >= 6 (WARN >= 3) |
Altman Z'' 5.16
(A) -0.04 = (Total Current Assets 9.07b - Total Current Liabilities 10.73b) / Total Assets 42.52b |
(B) 0.95 = Retained Earnings (Balance) 40.27b / Total Assets 42.52b |
warn (B) unusual magnitude: 0.95 — check mapping/units |
(C) 0.07 = EBIT TTM 3.16b / Avg Total Assets 44.05b |
(D) 1.76 = Book Value of Equity 39.89b / Total Liabilities 22.63b |
Total Rating: 5.16 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 68.19
1. Piotroski 8.0pt = 3.0 |
2. FCF Yield 3.13% = 1.57 |
3. FCF Margin 15.42% = 3.86 |
4. Debt/Equity 0.75 = 2.23 |
5. Debt/Ebitda 2.68 = -1.27 |
6. ROIC - WACC (= -1.07)% = -1.34 |
7. RoE 13.06% = 1.09 |
8. Rev. Trend 83.37% = 6.25 |
9. EPS Trend 56.18% = 2.81 |
What is the price of EMR shares?
Over the past week, the price has changed by -2.01%, over one month by -3.97%, over three months by -6.38% and over the past year by +21.24%.
Is Emerson Electric a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EMR is around 128.89 USD . This means that EMR is currently overvalued and has a potential downside of -1.06%.
Is EMR a buy, sell or hold?
- Strong Buy: 19
- Buy: 3
- Hold: 6
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the EMR price?
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 151 | 15.9% |
Analysts Target Price | 151 | 15.9% |
ValueRay Target Price | 144.4 | 10.9% |
Last update: 2025-10-04 03:50
EMR Fundamental Data Overview
P/E Trailing = 34.1154
P/E Forward = 20.0401
P/S = 4.2115
P/B = 3.7158
P/EG = 1.382
Beta = 1.279
Revenue TTM = 17.77b USD
EBIT TTM = 3.16b USD
EBITDA TTM = 4.72b USD
Long Term Debt = 8.28b USD (from longTermDebt, last quarter)
Short Term Debt = 6.10b USD (from shortTermDebt, last quarter)
Debt = 14.87b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.65b USD (from netDebt column, last quarter)
Enterprise Value = 87.53b USD (74.88b + Debt 14.87b - CCE 2.22b)
Interest Coverage Ratio = 9.21 (Ebit TTM 3.16b / Interest Expense TTM 343.0m)
FCF Yield = 3.13% (FCF TTM 2.74b / Enterprise Value 87.53b)
FCF Margin = 15.42% (FCF TTM 2.74b / Revenue TTM 17.77b)
Net Margin = 14.92% (Net Income TTM 2.65b / Revenue TTM 17.77b)
Gross Margin = 47.38% ((Revenue TTM 17.77b - Cost of Revenue TTM 9.35b) / Revenue TTM)
Gross Margin QoQ = 47.74% (prev 48.31%)
Tobins Q-Ratio = 2.06 (Enterprise Value 87.53b / Total Assets 42.52b)
Interest Expense / Debt = 0.85% (Interest Expense 126.0m / Debt 14.87b)
Taxrate = 20.98% (154.0m / 734.0m)
NOPAT = 2.50b (EBIT 3.16b * (1 - 20.98%))
Current Ratio = 0.85 (Total Current Assets 9.07b / Total Current Liabilities 10.73b)
Debt / Equity = 0.75 (Debt 14.87b / totalStockholderEquity, last quarter 19.87b)
Debt / EBITDA = 2.68 (Net Debt 12.65b / EBITDA 4.72b)
Debt / FCF = 4.62 (Net Debt 12.65b / FCF TTM 2.74b)
Total Stockholder Equity = 20.31b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.24% (Net Income 2.65b / Total Assets 42.52b)
RoE = 13.06% (Net Income TTM 2.65b / Total Stockholder Equity 20.31b)
RoCE = 11.05% (EBIT 3.16b / Capital Employed (Equity 20.31b + L.T.Debt 8.28b))
RoIC = 7.99% (NOPAT 2.50b / Invested Capital 31.25b)
WACC = 9.06% (E(74.88b)/V(89.75b) * Re(10.73%) + D(14.87b)/V(89.75b) * Rd(0.85%) * (1-Tc(0.21)))
Discount Rate = 10.73% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.75%
[DCF Debug] Terminal Value 66.70% ; FCFE base≈2.12b ; Y1≈1.88b ; Y5≈1.57b
Fair Price DCF = 33.56 (DCF Value 18.89b / Shares Outstanding 562.8m; 5y FCF grow -13.79% → 3.0% )
EPS Correlation: 56.18 | EPS CAGR: -0.24% | SUE: 0.13 | # QB: 0
Revenue Correlation: 83.37 | Revenue CAGR: 5.84% | SUE: -0.57 | # QB: 0
Additional Sources for EMR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle